Jonathan Steckbeck is the founder of Peptilogics, a biotechnology platform company that develops best-in-class novel peptide drugs for unmet medical needs. He also has a PhD in Biochemistry and Molecular Genetics from the University of Pittsburgh’s School of Medicine.
Amongst other problems, his company Peptilogics is focused on developing a new category of antibiotics. It has been 20 years since there was a genuinely new class of antibiotics, yet bacterial cells have continued to evolve and develop into drug-resistant infections. In this interview, Jonathan and Aaron discuss the founding of Peptilogics, why they’re focused on this new modality of medication, and the FDA approval process. Sign up for a Weekly Email that will Expand Your Mind. Jonathan Steckbeck’s Challenge; If there’s something that you want to do that doesn’t exist, go do it. Connect with Jonathan Steckbeck
Linkedin
Peptilogics Website If you liked this interview, check out episode 456 with Pete DeComo where we discuss the long, arduous process of developing a medical device and episode 443 with Blake Dube where we talk about better oxygen tanks. Text Me What You Think of This Episode 412-278-7680
2 Comments
6/19/2021 10:23:41 am
I’m here to appreciate your great help and the podcast update quite useful as well. I hope through the information various people able to get aware about the bio chemistry legend and able to get inspired as well. Keep it up with latest podcasts these would be amazing. 4/17/2022 08:35:36 am
Jonathan Steckbeck is the founder of Peptilogics, a company that has created peptide-based botanic medicines. Their mission is to heal patients with innovative natural products by providing safe options that can be prescribed to both physicians and healthcare providers. Leave a Reply. |
Show NotesFind links and information referenced in each episode. 
Archives
September 2022
|
RSS Feed